[go: up one dir, main page]

EP1904110A4 - Targeting cells with altered microrna expression - Google Patents

Targeting cells with altered microrna expression

Info

Publication number
EP1904110A4
EP1904110A4 EP06741167A EP06741167A EP1904110A4 EP 1904110 A4 EP1904110 A4 EP 1904110A4 EP 06741167 A EP06741167 A EP 06741167A EP 06741167 A EP06741167 A EP 06741167A EP 1904110 A4 EP1904110 A4 EP 1904110A4
Authority
EP
European Patent Office
Prior art keywords
microrna expression
targeting cells
altered microrna
altered
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06741167A
Other languages
German (de)
French (fr)
Other versions
EP1904110A1 (en
Inventor
Michael Zenon Michael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICA
Original Assignee
SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTRE
SOUTHERN ADELAIDE HEALTH SERVI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTRE, SOUTHERN ADELAIDE HEALTH SERVI filed Critical SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTRE
Priority to EP11161737A priority Critical patent/EP2377559A1/en
Publication of EP1904110A1 publication Critical patent/EP1904110A1/en
Publication of EP1904110A4 publication Critical patent/EP1904110A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/102—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP06741167A 2005-06-03 2006-06-02 Targeting cells with altered microrna expression Withdrawn EP1904110A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11161737A EP2377559A1 (en) 2005-06-03 2006-06-02 Targeting cells with altered microRNA expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68754705P 2005-06-03 2005-06-03
PCT/AU2006/000750 WO2006128245A1 (en) 2005-06-03 2006-06-02 Targeting cells with altered microrna expression

Publications (2)

Publication Number Publication Date
EP1904110A1 EP1904110A1 (en) 2008-04-02
EP1904110A4 true EP1904110A4 (en) 2009-02-11

Family

ID=37481150

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06741167A Withdrawn EP1904110A4 (en) 2005-06-03 2006-06-02 Targeting cells with altered microrna expression
EP11161737A Withdrawn EP2377559A1 (en) 2005-06-03 2006-06-02 Targeting cells with altered microRNA expression

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP11161737A Withdrawn EP2377559A1 (en) 2005-06-03 2006-06-02 Targeting cells with altered microRNA expression

Country Status (5)

Country Link
EP (2) EP1904110A4 (en)
JP (1) JP2008541737A (en)
AU (1) AU2006254732A1 (en)
CA (1) CA2610702A1 (en)
WO (1) WO2006128245A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771563A2 (en) 2004-05-28 2007-04-11 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
ES2503739T3 (en) 2004-11-12 2014-10-07 Asuragen, Inc. Procedures and compositions involving miRNA and miRNA inhibitor molecules
WO2008015662A1 (en) † 2006-08-04 2008-02-07 Dublin City University A method of producing recombinant biological products
EP2115138A2 (en) * 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
AU2007299804A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. MiR-200 regulated genes and pathways as targets for therapeutic intervention
AU2007299748A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
CA2663812A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-143 regulated genes and pathways as targets for therapeutic intervention
EP2111408A4 (en) * 2007-01-17 2010-02-03 Univ Johns Hopkins COMPOSITIONS AND METHODS COMPRISING MICROARNS FOR TREATING NEOPLASIA
AU2008232316A1 (en) * 2007-03-26 2008-10-02 Newcastle Innovation Limited Therapeutic targets and molecules
US20100113577A1 (en) * 2007-04-11 2010-05-06 Bin Shi Isolated nucleic acid molecules corresponding to micro rna 145 (mirna-145) and their use in treating colon cancer
CA2683053A1 (en) * 2007-04-19 2008-10-30 Vib Vzw Oligonucleotide compositions for the treatment of alzheimer's disease
NZ583024A (en) 2007-07-31 2012-04-27 Regents The Univeristy Of Texas System Board Of An agonist of miR-29a, miR-29b or miR-29c that prevents tissue fibrosis and uses thereof
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
JP2009100687A (en) * 2007-10-24 2009-05-14 Chiba Univ Method for detecting bladder cancer based on microRNA expression profiling
EP2280078B1 (en) * 2008-03-27 2016-05-18 Kuroda, Masahiko Marker for determination of breast cancer, test method, and test kit
EP2112235A1 (en) * 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
EP2285960B1 (en) 2008-05-08 2015-07-08 Asuragen, INC. Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
US20110098346A1 (en) * 2008-05-19 2011-04-28 Agency For Science, Technology And Research Nucleic acid molecule and method of targeting gene expression to gliomas
WO2010075101A2 (en) * 2008-12-15 2010-07-01 Dcb-Usa, Llc Treating picornavirus infection by targeting microrna mir-141
PT2424571T (en) 2009-04-30 2020-05-06 Ospedale San Raffaele Srl Gene vector
WO2010135714A2 (en) * 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
EP2341145A1 (en) * 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011111715A1 (en) * 2010-03-09 2011-09-15 協和発酵キリン株式会社 Nucleic acid capable of regulating cell cycle
US8906875B2 (en) 2010-03-12 2014-12-09 The Brigham And Women's Hospital, Inc. Methods of treating vascular inflammatory disorders
ES2573669T3 (en) 2010-07-08 2016-06-09 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for diabetes
JP2014506789A (en) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド miR-124 synthetic mimics
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
ITRM20110685A1 (en) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And MICRORNA FOR CARDIAC REGENERATION THROUGH THE INDUCTION OF THE PROLIFERATION OF CARDIAC MYCYCLES
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
JP5704576B2 (en) * 2012-12-28 2015-04-22 国立大学法人 千葉大学 Method for detecting bladder cancer based on microRNA expression profiling
JP5704575B2 (en) * 2012-12-28 2015-04-22 国立大学法人 千葉大学 Method for detecting bladder cancer based on microRNA expression profiling
JP5812361B2 (en) * 2013-07-11 2015-11-11 国立研究開発法人医薬基盤・健康・栄養研究所 Novel Ad vector containing gene expression control mechanism
CN104120128B (en) * 2014-07-02 2016-04-20 重庆贝羿生物科技有限公司 A kind of nucleic acid molecule of the separation for promoting vhl gene to express and promotor and preparation thereof
CN104726500B (en) * 2015-03-12 2017-09-12 中国人民解放军第二军医大学 Application of the MicroRNA26b 3p inhibitor in people's umbilical cord derived mesenchymal stem cell is prepared
ES2810701T5 (en) 2015-10-05 2024-07-11 Modernatx Inc Procedures for the therapeutic administration of messenger ribonucleic acid drugs
US11293065B2 (en) 2016-03-14 2022-04-05 Aelan Cell Technologies, Inc. Compositions and methods for the quality control of stem cell preparations
CA3031670A1 (en) * 2016-07-26 2018-02-01 Senti Biosciences, Inc. Spatiotemporal regulators
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
GB201805287D0 (en) * 2018-03-29 2018-05-16 Univ Edinburgh Haematoietic stem cell treatment
US10704048B2 (en) 2018-06-14 2020-07-07 Ovid Therapeutics Inc. Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
CN112301033B (en) * 2020-11-24 2021-11-19 南通大学 miR-30a-5p and application thereof in promoting nerve regeneration and repairing peripheral nerve injury
CN113750111A (en) * 2021-09-23 2021-12-07 清华大学深圳国际研究生院 Use of a miRNA-15A for the treatment of tumors with high expression of KIF3B

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078096A2 (en) * 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054494A2 (en) * 2003-11-26 2005-06-16 University Of Massachusetts Sequence-specific inhibition of small rna function
EP2295604B1 (en) * 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
WO2005111211A2 (en) * 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micronas and uses thereof
AU2005248149A1 (en) * 2004-05-26 2005-12-08 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
JP5956709B2 (en) * 2005-05-27 2016-07-27 オスペダーレ サン ラファエレ エス．アール．エル Gene vector

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078096A2 (en) * 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHN BINO ET AL: "Human MicroRNA targets.", PLOS BIOLOGY NOV 2004, vol. 2, no. 11, November 2004 (2004-11-01), pages e363, XP009109996, ISSN: 1545-7885 *
MANSFIELD JENNIFER H ET AL: "MicroRNA-responsive 'sensor' transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US, vol. 36, no. 10, 1 October 2004 (2004-10-01), pages 1079 - 1083, XP002394622, ISSN: 1061-4036 *
See also references of WO2006128245A1 *

Also Published As

Publication number Publication date
CA2610702A1 (en) 2006-12-07
WO2006128245A1 (en) 2006-12-07
EP2377559A1 (en) 2011-10-19
JP2008541737A (en) 2008-11-27
EP1904110A1 (en) 2008-04-02
AU2006254732A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
EP1904110A4 (en) Targeting cells with altered microrna expression
IL197444A0 (en) Cell culture improvements
GB0720484D0 (en) Cells
GB2424118B (en) Fuel cells
GB2440434B (en) Fuel cells
GB2440435B (en) Fuel cells
EP2184349A4 (en) Isolated cell mass
GB0613756D0 (en) Cell culture medium
EP2028264A4 (en) Cell incubator
GB0608079D0 (en) Fuel cells
GB2438352B (en) Cell culture chamber
GB0517382D0 (en) Cell culture
EP2118278A4 (en) Stem cell gene targeting
GB2440366B (en) Solar cells
GB0503918D0 (en) Cell
GB0606671D0 (en) Cell Culture
GB0601101D0 (en) Solar cell
GB0522564D0 (en) Cells
GB0600960D0 (en) Whole cell biosensor
GB0602082D0 (en) Cells
GB2467284B (en) Sulfatase enzymes
PL380136A1 (en) Fotovoltaic cell
GB0700936D0 (en) Cells
IL195358A0 (en) Solar cells arrangement
AU2007900858A0 (en) Cell arrangement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090114

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/48 20060101ALI20090108BHEP

Ipc: C12N 15/11 20060101ALI20090108BHEP

Ipc: A61K 48/00 20060101AFI20070202BHEP

Ipc: C12Q 1/68 20060101ALI20090108BHEP

Ipc: A61P 35/00 20060101ALI20090108BHEP

17Q First examination report despatched

Effective date: 20090401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120323